Thrombotic thrombocytopenic purpura is a hematologic disease with a high mortality rate that affects multiple organ systems. It is caused by a deficiency of a metalloprotease known as the ADAMTS-13 enzyme. Patients can present with fever, hemolytic anemia, thrombocytopenia, kidney injury, and neurological symptoms. Here we present a case of a female with TTP who was initially diagnosed with benign paroxysmal positional vertigo (BPPV). Her initial symptoms were vertigo, blurry vision, and gait imbalance, which were accompanied by elevated total bilirubin, acute kidney injury, thrombocytopenia, and normal hemoglobin. When the patient followed up in her primary care clinic, she was found to have worsening renal function, hemolytic anemia, and severe thrombocytopenia. She was subsequently diagnosed with TTP and referred to the emergency department (ED) where she received emergent treatment with therapeutic plasma exchange (TPE) and later rituximab. This case stresses the importance of considering TTP in patients presenting with symptoms and laboratory values suggestive of the disease, even when anemia is not present.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872677PMC
http://dx.doi.org/10.7759/cureus.78305DOI Listing

Publication Analysis

Top Keywords

thrombotic thrombocytopenic
8
thrombocytopenic purpura
8
hemolytic anemia
8
kidney injury
8
common symptom
4
symptom critical
4
critical diagnosis
4
diagnosis vertigo
4
vertigo clue
4
clue thrombotic
4

Similar Publications

[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].

Zhonghua Xue Ye Xue Za Zhi

January 2025

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow Universtiy, Suzhou 215006, China.

To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura (iTTP). This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment. All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib.

View Article and Find Full Text PDF

Real-world evaluation of a novel automated method for measuring ADAMTS13 activity using the Ceveron® s100 analyzer.

J Thromb Haemost

March 2025

Service d'Hématologie biologique, Hôpital Lariboisière, AP-HP.Nord, Université Paris Cité, Paris, France; INSERM UMR-S 1138, Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Paris, France.

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by a severe functional deficiency of ADAMTS13. Measuring ADAMTS13 activity is crucial for diagnosing TTP (<10 IU/dL), monitoring treatments, and detecting relapses (<20 IU/dL). The Technofluor® assay allows a rapid ADAMTS13 activity measurement using the CEVERON® s100 analyzer.

View Article and Find Full Text PDF

The 2024 Guidelines for the Primary Prevention of Stroke, recently updated by the American Heart Association and the American Stroke Association, serve as an essential resource for clinicians aiming to reduce the growing impact of cerebrovascular disease. These guidelines emphasize modifiable risk factors and population-specific considerations, covering a range of cardiovascular conditions, including hypertension, diabetes, atherosclerotic disease, and genetic predispositions to stroke. However, a notable omission in these guidelines is the absence of specific recommendations for patients with thrombotic thrombocytopenic purpura.

View Article and Find Full Text PDF

Thrombotic microangiopathy (TMA) represents a diverse group of conditions characterized by the presence of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and ischemic end-organ injury. Thrombotic thrombocytopenic purpura (TTP) is an important cause of TMA requiring urgent identification and therapeutic plasma exchange (TPE). Cancer-related TMA is commonly misdiagnosed as TTP.

View Article and Find Full Text PDF

We present an unusual case of complement-mediated thrombotic microangiopathy (formerly known as atypical hemolytic uremic syndrome) associated with inflammatory disease in a young patient. A 26-year-old male patient with no significant past medical history presented to our emergency department with a four-week history of diffuse, moderate, cramping, non-radiating abdominal pain with no known aggravating or relieving factors. Abdominal pain was associated with nausea, vomiting, and bloody stools.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!